Influenza Flashcards

1
Q

when does influenza occur and why is it said to be related to the sun?

A

From the latin word ‘influentia’ – meaning influence of the stars

Seasonal influenza occurs during winter months:
Dec – Feb in the Northern Hemisphere
Jun – Aug in the Southern Hemisphere

More severe epidemics of influenza occur every 11 years; same as increased ‘sunspot activity’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are 20th century pandemics of influenza?

A

1918-9 ‘Spanish Flu’ (A/H1N1)
† 20-100 million deaths
1957-8 ‘Asian Flu’ (A/H2N2)
† 1-1.5 million deaths
1968-9 ‘Hong Kong Flu’ (A/H3N2)
† 0.75-1 million deaths
2009-10 ‘Swine Flu’ (A/H1N1)
† approximately 285.000 deaths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

describe the surface proteins of influenza?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the mechanism of antigenic drift?

A

Mechanism of genetic variation within the virus
Occurs continually over time, small on-going point mutations in the genes coding for antibody binding-sites
May change the antigenic properties and eventually the immune system will not combat the virus as well
Causes worse than normal epidemics & vaccine mismatch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is the mechanism of antigenic shift?

A

Abrupt major change in the virus, resulting in new H/N combinations

The genetic change that enables a flu strain to jump from one animal species to another

The process by which two or more different strains of a virus combine to form a new subtype, resulting in new H/N combinations

Reassortment of the virus’ gene segments

With new antigenic properties the population at risk is unprotected and this can lead to PANDEMICS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

how do seasonal and pandemic flu differ?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the requirements for a pandemic?

A

Human pathogenicity

‘New’ virus (antigenic shift)
- susceptible population

🗹 Efficient person-person
transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the clinical features of influenza?

A

Incubation period 2-4 days (range 1-7 days)

Abrupt fever up to 41°C (commonly 38-40°C) which lasts 3 days (range 1-5 days)

Plus 2 or more of: Cough, [sore throat, rhinorrhoea], myalgia, headache, malaise.

Predominance of systemic symptoms

Less common symptoms: Nausea, vomiting, diarrhoea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ifluenza like illness?

A

Fever (>38°C) and
Cough
Onset within the last 10 days

(if requires hospitalization defined as severe acute respiratory infection (SARI))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

symptoms of swine flu?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how is influenza transmitted?

A

Airborne – person ⭢ person by large droplets >5 microns
Contact – direct (person ⭢ person)
– indirect (person ⭢ fomite ⭢ person)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

virus shedding?

A

First 4 days of illness (range 1-7 days)
Longer in young children & immunocompromised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

virus survival?

A

24-48 hours on non-porous surfaces
8-12 hours on porous surface e.g. tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are risk factors for complicated influenza?

A

Neurological, hepatic, renal, pulmonary and chronic cardiac disease

Diabetes mellitus

Severe immunosuppression

Age over 65 years

Pregnancy (including up to two weeks post partum)

Children under 6 months of age

Morbid obesity (BMI ≥40)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are common respiratory complications of influenza?

A

Acute Bronchitis

Secondary Bacterial Pneumonia (~20%)
Appears 4-5 days after start of ‘flu

RESPIRATORY:
Primary viral pneumonia
- appears common in human cases of avian influenza (H5N1)
- rapid respiratory failure; within 48 hours
- mortality >40%; within 7 days

CARDIAC:
Myocarditis/pericarditis

CNS:
Transverse myelitis/Guillain-Barre
Myositis & Myoglobinuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ENCEPHALITIS LETHARGICA

A

Fever, headache
External ophthalmoplegia
Lethargy
Sleep reversal

25 % mortality
Postencephalitic Parkinsonism
Serology +ve ’flu A
Paralleled 1918-19 pandemic

17
Q

what diagnosis and investigations should be done for influenza?

A

Viral nose and throat swabs/VTS (Molecular detection /PCR; using flocked swabs)
Chest X-ray – pneumonitis/pneumonia/ARDS
Blood culture
Pulse oximetry – SpO2 <92% need ABG and oxygen
Respiratory rate !
U & E’s, FBC, CRP (CRP monitoring recovery of pneumonia - should halve in 4 days)

18
Q

sECONDARY BACTERIAL PNEUMONIA

A

Patients with ‘flu symptoms and a fever for > 4days – should have an urgent CXR

Severity assessment – use C(U)RB-65 score
Confusion
Urea >7mmol/l
Respiratory rate >30mm
Blood Pressure (diastolic <60 or systolic <90)
>65 years of age

C(U)RB score: Risk of death in the next 30 days (0=0.6%, 1=3.2%, 2=13%, 3=17%, 4=41.5%, 5=57%)

19
Q

ANTIVIRAL THERAPY

A

Use ASAP and within 48hours of symptom onset !
But, in complicated illness: “…should always be given, no matter how long after onset of illness…”

OSELTAMIVIR (TAMIFLU) - Oral
Dose : Over 13 years – 75mg every 12 hours for 5 days
Adverse Effects:
Common – Nausea, vomiting, abdominal pain, diarrhoea
Less Common – Headache, hallucinations, insomnia and rash
Cautions: Renal dosing needed

ZANAMIVIR (RELENZA) – Inhaled & or I.V.
Available only as a dry powder inhaler
Dose: Over 12 years – 10mg inhaled daily for up to 10 days
Adverse Effects: Rare – occasional bronchospasm

20
Q

OTHER ANTIVIRAL THERAPY

A

Peramivir (Alpivab®)
Neuroaminidase inhibitor
Licensed in USA and approved by European Medicines Agency (EMA) 1st May 2018 !
Intravenous infusion, for uncomplicated influenza
Favipiravir (Avigan®, Toyama Chemicals Ltd)
Viral RNA polymerase inhibitor
Licenced in Japan for ‘re-emerging influenza viruses’
Oral medication
Baloxavir Marboxil (Xofluza®, Roche)
Endonuclease inhibitor
One single dose
(Amantadine & Rimantadine notl used due to resistance)

21
Q

BREASTFEEDING
Only tiny amounts of Oseltamivir in milk
Current guidance is – Oral Oseltamivir

A

PREGNANCY
Current guidance (PHE Sep 2017) is:
Antivirals have been recommended…due to the adverse outcomes …in this group
Oseltamivir remains first line option…
Recent studies (2014) suggests there is no evidence of harm of either oseltamivir or zanamivir
FDA pregnancy category C: No malformation, maternal toxicity or embryotoxcity were observed in animal studies. No data available in humans.

22
Q

When does an individual become non-infectious?

A

IMMUNOCOMPETENT ADULTS

24hrs after last ‘flu symptoms (fever & cough)
Or when anti-viral therapy completed
Which ever is longer

23
Q

PROTECTION FOR HEALTHCARE STAFF

A

For most patients with proven or suspected ‘flu’

Surgical face mask
Plastic apron
Gloves

Wash hands after any examination

Seeing patients who are receiving a Nebuliser, NIV etc – with aerosolised virus

‘Face-fit’ FFP3 respirator mask

24
Q

VACCINATION

A

Seasonal Flu vaccine’

25
Q

Seasonal Flu vaccine’

A

Prepared each year using viruses considered most likely to be circulating in the forthcoming winter

Grown in chick embryos (therefore C.I. in those with egg allergy)

Chemically inactivated and purified, trivalent vaccines
Containing 2 type A & 1 type B subtype viruses

Single 0.5 ml intramuscular injection

Only adverse effect in large placebo controlled tria